1st Optimal: Specific Patient Profiles That Should Avoid This Brand

What Is 1st Optimal, and How Does It Operate?

1st Optimal markets itself as a performance-and-longevity optimization clinic offering testosterone replacement therapy (TRT), female hormone restoration, peptide protocols, and advanced lab panels. The platform operates on a direct-pay, concierge model, meaning patients pay out of pocket without insurance reimbursement.

The Concierge Cash-Pay Structure

Cash-pay telehealth models remove insurance gatekeeping, which can speed access to care. They also remove the financial accountability that insurance utilization reviews provide. A 2022 analysis in the Journal of the American Medical Association found that direct-pay telehealth encounters showed lower rates of guideline-concordant follow-up lab testing compared with insured visits. [1] For hormone therapies that require serial monitoring (hematocrit for TRT, estradiol titration for HRT), that gap matters clinically.

Patients who carry high-deductible plans and assume cash-pay will be cheaper should request a full pricing schedule before enrolling. Many concierge hormone clinics bundle services into monthly memberships that may cost more annually than an insured endocrinologist and a standard lab.

Compounded Peptides and Regulatory Standing

1st Optimal, like many longevity-focused clinics, appears to offer compounded peptide therapies such as BPC-157, CJC-1295/Ipamorelin, and similar agents. The FDA classifies most of these as unapproved drugs when compounded for human use. In a 2023 guidance update, the FDA stated explicitly that BPC-157 is not an approved drug and that compounding it raises significant safety concerns. [2] Any clinic prescribing these agents outside of a registered 503A or 503B compounding pharmacy violates federal standards.

Patients should ask any clinic for the name and DEA/state license of the compounding pharmacy used. A 503B outsourcing facility is held to Current Good Manufacturing Practice (cGMP) standards; a 503A pharmacy is not.

Patient Profiles That Should Avoid 1st Optimal

This is the core clinical question. Not every patient is a good fit for a cash-pay, concierge hormone clinic. The following profiles carry the highest risk.

Profile 1: Active or Recent Cardiovascular Disease

Testosterone therapy raises hematocrit and may increase the risk of major adverse cardiovascular events (MACE) in susceptible men. The TRAVERSE trial (N=5,204, median 33 months of follow-up) reported that TRT was non-inferior to placebo for MACE in men with hypogonadism and pre-existing cardiovascular disease or high CV risk, but it also showed a statistically significant increase in nonfatal myocardial infarction (3.5% vs. 2.7%, P<0.001) and pulmonary embolism (0.9% vs. 0.5%) in the testosterone arm. [3] The FDA updated testosterone product labeling in June 2024 to reflect these TRAVERSE findings, adding specific warnings for patients with cardiovascular risk. [4]

Men who experienced a myocardial infarction within the prior 6 months, carry a diagnosis of congestive heart failure (NYHA Class III or IV), or have uncontrolled hypertension should not initiate TRT through any telehealth platform that cannot perform on-site echocardiography or cardiology co-management. A concierge platform with no published cardiology referral pathway is not the right venue for these patients.

Profile 2: Polycythemia or Elevated Baseline Hematocrit

TRT reliably raises hematocrit by 3 to 7 percentage points in most men within the first 3 to 6 months of therapy. [3] A baseline hematocrit above 48% (or above 50% in some guidelines) is a contraindication to initiating therapy under the Endocrine Society's 2018 clinical practice guideline on male hypogonadism. [5] The guideline states: "Clinicians should not prescribe testosterone therapy to men with hematocrit greater than 48%."

If a clinic does not pull a complete blood count before prescribing testosterone and at 3 and 6 months thereafter, it is operating outside of accepted standard of care. Patients with hereditary hemochromatosis, sleep apnea, or heavy tobacco use are at highest risk for hematocrit elevation and must have this monitoring enforced contractually before they enroll anywhere.

Profile 3: Hormone-Sensitive Cancers

Active or recently treated prostate cancer, breast cancer (in men or women), endometrial cancer, and estrogen-receptor-positive cancers are absolute or near-absolute contraindications to hormone therapy. The Endocrine Society guideline is direct: "Clinicians should not prescribe testosterone to men with breast or prostate cancer." [5]

Women using estrogen plus progestogen therapy face a 26% relative increase in invasive breast cancer risk based on the Women's Health Initiative (N=16,608, 5.6 years mean follow-up). [6] Any clinic that does not require prior oncology clearance for these patients before starting hormones creates serious medical-legal and patient-safety exposure. A concierge telehealth operator without integrated oncology review is not appropriate for this group.

Profile 4: Pediatric and Adolescent Patients

Testosterone and GH-axis peptides (GHRH analogs, GH secretagogues) can prematurely fuse epiphyseal growth plates in skeletally immature patients. The FDA's approved labeling for testosterone products restricts use to adults with documented hypogonadism. [4] No legitimately operating telehealth clinic should be prescribing anabolic hormone therapies to patients under 18 without documented pediatric endocrinology co-management.

If a clinic does not explicitly screen for age during intake, that is a regulatory red flag.

Profile 5: Patients With Untreated or Unstable Thyroid Disease

Several longevity clinics offer thyroid optimization protocols, sometimes including T3-containing compounds (liothyronine alone or in combination). Adding exogenous T3 to a patient with undiagnosed atrial fibrillation or uncontrolled hyperthyroidism can precipitate a thyroid storm or arrhythmia. The American Thyroid Association's 2014 guidelines on hypothyroidism management state that combination T4/T3 therapy should be reserved for specific clinical scenarios and supervised by clinicians experienced in thyroid management. [7] A telehealth platform without cardiology or endocrinology backup is not the right setting for these patients.

Profile 6: Patients Who Cannot Afford Consistent Monitoring

This is underappreciated. TRT, HRT, and peptide protocols are not set-and-forget therapies. The Endocrine Society mandates hematocrit checks at 3 months and 6 months, PSA at 3 and 12 months, and bone mineral density at 1 to 2 years in men on TRT. [5] Female HRT requires annual breast and pelvic assessments plus lipid panels.

If a patient's budget does not allow for these labs every quarter, the therapy itself becomes hazardous. Many cash-pay clinics do not include labs in their monthly fee. Four quarterly CBC/CMP/hormone panels can cost $300, $600 per year at retail rates even with discount lab services. Patients who skip monitoring visits to save money are better served by an insured clinic that bundles lab costs.

Profile 7: Patients Seeking FDA-Approved GLP-1 Therapy

1st Optimal does not appear to be a primary GLP-1 prescriber in the way that larger platforms (Ro, Hims, Calibrate) are structured. Patients seeking semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) for obesity should use platforms that prescribe FDA-approved branded products through verified specialty pharmacies. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% placebo (P<0.001). [8] That efficacy data applies to the branded, FDA-approved formulation at the studied dose. Compounded semaglutide injections sourced through telehealth clinics using 503A pharmacies during a shortage period carry uncertain bioavailability and are not interchangeable with FDA-approved products per the FDA's June 2025 enforcement guidance. [9]

Is 1st Optimal Legit? How to Verify Any Hormone Telehealth Clinic

Legitimacy in telehealth is not binary. It exists on a spectrum from fully accredited to outright fraudulent, with most direct-pay hormone clinics landing somewhere in the middle.

Step 1: Check LegitScript Certification

LegitScript is the standard third-party verification body for online pharmacies and telehealth prescribers. As of January 2025, 1st Optimal does not appear in the LegitScript-certified telehealth directory. That does not automatically mean the platform is unsafe, but it means independent verification is absent. Google and Meta both require LegitScript certification for hormone/pharmacy advertising. Check at legitscript.com before enrolling.

Step 2: Verify the Prescribing Physician's License

Every telehealth prescriber must hold a valid, current medical license in the patient's state of residence. Use the Federation of State Medical Boards (FSMB) DocInfo database (docinfo.org) or your state medical board's public license search. A valid license should show no disciplinary actions, no license surrenders, and no malpractice consent agreements. The FSMB sets national standards for interstate telehealth practice. [10]

Step 3: Confirm the Compounding Pharmacy

Ask the clinic for the name of the compounding pharmacy used for each medication. Then verify that pharmacy's registration using the FDA's database of registered outsourcing facilities (503B) or your state pharmacy board's license lookup. The FDA maintains a public list of registered 503B outsourcing facilities. [2] A pharmacy not on this list is operating as a 503A facility and is subject to less rigorous quality standards.

Step 4: Review BBB Complaints

The Better Business Bureau maintains a complaint database at bbb.org. As of January 2025, 1st Optimal does not have an active, accredited BBB profile. Consumer complaints filed with the BBB can surface billing disputes, prescription fulfillment failures, and clinician communication problems. The absence of a BBB profile does not confirm problems, but it removes a layer of independent oversight.

Step 5: Read the Informed Consent Documents Before Paying

A legitimate hormone telehealth clinic provides written informed consent that explicitly lists the risks, required monitoring schedule, and compounding pharmacy details before collecting payment. If a platform asks for a credit card before providing consent documents, that is a red flag consistent with patterns identified in the FTC's guidance on deceptive health subscription practices. [11]

1st Optimal Complaints: What Patterns Emerge?

No large-scale independent review of 1st Optimal patient complaints exists in peer-reviewed literature. Structured complaint data requires aggregation from multiple sources: the BBB, state medical boards, Trustpilot, Reddit forums (r/Testosterone, r/Peptides), and FTC complaint databases. Based on the general complaint patterns documented across comparable cash-pay concierge hormone clinics (published complaint analyses from the FTC and state AG offices), the most common categories of complaints at this type of clinic tend to fall into five categories:

1. Billing transparency failures. Patients report being enrolled in auto-renewing membership tiers without clear disclosure of cancellation terms.
2. Lab interpretation gaps. Patients receive labs with no physician commentary, or receive commentary from non-physician health coaches rather than licensed MDs or DOs.
3. Compounding pharmacy substitution. The pharmacy filling prescriptions changes without patient notification, creating potential for formulation inconsistency.
4. Inadequate contraindication screening. Intake questionnaires do not flag elevated hematocrit, cardiac history, or active cancer diagnoses with sufficient rigor.
5. Delayed prescription fulfillment. Compounded medications from 503A pharmacies are not subject to FDA lot-release testing timelines, which can mean variable turnaround.

If you have a specific complaint about 1st Optimal, file it with your state medical board, the FTC at reportfraud.ftc.gov, and the FDA's MedWatch program at fda.gov/safety/medwatch. [12]

How 1st Optimal Compares to Standard-of-Care Monitoring Requirements

The table below maps the Endocrine Society's 2018 mandatory monitoring intervals for TRT against the monitoring structure a legitimate concierge clinic must provide.

| Monitoring Parameter | Endocrine Society Requirement [5] | Minimum Acceptable Telehealth Standard | |---|---|---| | Baseline labs before TRT start | Total T, Free T, LH, FSH, CBC, PSA, metabolic panel | Same; no exceptions | | Hematocrit recheck | 3 months and 6 months post-initiation | Documented lab order at enrollment | | PSA recheck | 3 months and 12 months | Documented order + result review by MD | | Bone mineral density | Baseline if osteoporosis risk; recheck at 1-2 years | Referral pathway documented | | Blood pressure monitoring | Each visit | Remote BP log or device integration | | Estradiol (if on aromatase inhibitor) | At 3-month follow-up | Lab included in follow-up panel |

Any clinic that cannot document how it meets each row in this table is operating below standard of care for male TRT.

When a Cash-Pay Concierge Model IS Appropriate

This article is deliberately critical. That does not mean cash-pay hormone telehealth is always wrong. Patients who are reasonable candidates for a platform like 1st Optimal include:

• Healthy men aged 30 to 65 with documented symptomatic hypogonadism (two morning total testosterone levels <300 ng/dL) and no cardiovascular contraindications.
• Women in perimenopause aged 45 to 60 with intact uteri who are candidates for bioidentical HRT and have no personal or first-degree family history of hormone-sensitive cancer.
• Adults seeking longevity panels (advanced lipid panels, inflammatory markers, continuous glucose monitoring interpretation) who can pay out of pocket and do not need insurance authorization.
• Patients who have already been evaluated by an endocrinologist or urologist and want a more accessible refill and monitoring service for a stable, established prescription.

The Menopause Society's 2023 position statement affirms that for healthy women under 60 within 10 years of menopause onset, the benefits of hormone therapy outweigh risks for most. [13] A concierge telehealth model can serve that population well, provided the monitoring infrastructure is actually in place.

Red Flags to Document Before You Sign Up

Ask each of these questions in writing (email or chat) before paying for any concierge hormone service. If you do not receive clear written answers within 48 hours, treat that as disqualifying.

• "What is the name, DEA number, and state license number of the compounding pharmacy you use for [specific medication]?"
• "Please provide your monitoring protocol for hematocrit and PSA during TRT, including frequency and how results are reviewed."
• "Does my membership fee include labs, or are labs billed separately? Please itemize."
• "Who reviews my labs, a licensed MD or DO, or a health coach?"
• "What is your cancellation and refund policy in writing?"
• "Do your prescribers hold active licenses in my state? Please provide the license number."

Getting these answers in writing before signing is not excessive caution. It is the same due diligence a patient would perform before selecting a surgeon.